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2Abstract
The neurodegenerative disorder Alzheimer’s disease (AD) is the most common form of
dementia. It is characterized by progressive impairment of cognitive functions and
behavior. To distinguish clinically AD from other forms of dementia is an ongoing
challenge. In addition, although mild cognitive impairment (MCI) is recognized as a risk
factor for dementia, it remains a challenge to predict on an individual level who will convert
to become demented.
Amyloid ß©(Aß) is one of the crucial pathological findings in AD. Recently, amyloid tracers
for PET imaging have been developed successfully which may offer the unique possibility
for measuring fibrillar Aß load in the living brain. Therefore, in the near future positron
emission tomography (PET) may become an important tool for in vivo amyloid imaging
contributing to early (differential) diagnosis as well as evaluation of treatment response in
AD. Moreover, Aß may play a role in prediction the conversion of MCI to AD. In this paper
we review the recent development of the molecular imaging technique PET and its
different radiopharmaceuticals on the trail for imaging amyloid in AD and the conversion of
MCI to AD.
3Introduction
Alzheimer’s disease, amyloid and tangles
More than 100 years ago Alois Alzheimer presented the case of Auguste D, a peculiar
case of a disease of the cerebral cortex [1]. Kraepelin realized the importance of this
report, included Alzheimer’s observation in his textbook on Psychiatry and gave it the
name “Alzheimer’s disease” (AD) [2]. Since then, there has been a remarkable progress in
understanding the pathophysiological events of AD particularly in the past two decades.
Although several damages involving the cellular, molecular and biochemical part of the
central nervous system were found, the ultimately cause of AD still remains unknown.
According to the main hypothesis, the amyloid cascade hypothesis, the central event in AD
is an imbalance between Amyloid ß (Aß) production and clearance, with increased Aß
production in familial AD and a decrease of Aß clearance in sporadic AD [3].
Consequently, soluble Aß is undergoing a conformational change to a high ß-sheet
content and finally aggregates into soluble oligomers and larger insoluble fibrils called
plaques [4]. This process is a trigger for the synthesis of other misformed Aß species [5],
finally leading to an impairment of neuronal and synaptic function which results in
neurotransmitter deficits and cognitive as well as behavioural symptoms.
Another feature in AD pathology leading to neuronal dysfunction and cognitive symptoms
are neurofibrilary tangles (NFT). NFT are composed of abnormal hyperphosphorylated tau
proteins which reduce the ability to bind microtubules and lead to cytoskeletal
degeneration and neuronal death [6]. Besides, other processes like oxidative stress,
inflammatory reactions and microglia activation may play an additional role in AD
pathology [7].
Mild cognitive impairment
Currently a definite diagnosis of AD is only established by post mortem histopathological
analysis of the brain. Lack of accessibility of brain tissue for histopathological analysis
forces the use of other diagnostic criteria. Therefore, cognitive assessments are central to
clinical diagnosis and management of dementias, as well as to the assessment of
behavioral and neuropsychological functions [8]. For AD, both the Diagnostic and
Statistical Manual, 3rd ed, revised (DSM-IIIR) and the National Institute of Neurologic
Communicative Disorders and Stroke – Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA) criteria achieved a good diagnostic sensitivity (average
481% across studies), but a low specificity (average across studies 70%) for 'probable' AD,
based on studies with post-mortem confirmation [8].
The appearance of neuropathological hallmarks like Aß and NFT probably occur years
before clinical symptoms of AD [9] which are characterized by a progressive impairment of
cognitive functions. After a 5–10 years lasting stage of mild cognitive impairment (MCI),
clinically manifest dementia is diagnosed frequently [10-12], initially affecting mainly the
declarative memory [13,14]. As a result, MCI patients are regarded as a risk group for
developing AD. The annual conversion rate of patients with MCI is generally believed to be
around 10–15%, which means that in three years approximately half of the patients with
MCI will probably develop clinical AD [15]. However, until now it is not possible to
discriminate who will convert from MCI to AD. Clinical features alone were insufficient to
predict development of dementia [16]. Consequently, the search for specific markers of AD
and for non-invasive tools in the assessment of regional brain pathology is in demand. In
this context, the recent successful development of amyloid PET imaging may be of
importance.
Aims of the review
Modern imaging technologies such as Positron Emission Tomography (PET) and Magnetic
Resonance Imaging (MRI) may allow the detection of molecular pathological changes in
MCI and several forms of dementia. These methods may be superior to
neuropsychological testing in the diagnosis of AD [17,18] and improve to predict the
conversion of MCI cases to AD. Additionally these methods provide specific differential
diagnosis of the type of disorder, which is underlying cognitive symptoms, and help to
assess the association of particular symptoms with a particular brain location. Finally, such
a unique technique may be of value to monitor disease progression, and might be of value
to evaluate potential neuroprotective drugs.
In the current article we provide an overview of studies on amyloid PET showing their
potency and limitations in distinguishing MCI converters from non-converters, and their
potential role in the diagnosis of (early) AD, as well as in monitoring disease progression
and therefore its potential to assess treatment response.
Other imaging techniques like scintigraphic studies of neuronal transmitters and receptor
status appearing in the course of AD are not discussed here.
5Positron Emission Tomography (PET)
Functional imaging as single photon emission computed tomography (SPECT) and PET
have provided more insight into the understanding of neuronal interactions and
pathologies of the human brain. These studies have enabled the measurement of cerebral
blood flow, glucose metabolism, several aspects of neurotransmitter systems and uptake
of aminoacids, among others. PET studies are usually evaluated visually as well as
quantitatively, preferably compared to an age-matched database.
18F-fluorodeoxyglucose (18F-FDG)-PET
Clinical brain studies are often performed with the radiolabeled glucose analog 18F-FDG, a
PET-tracer for in vivo assessment of regional cerebral glucose metabolism which parallels
the transport of glucose into cells thereby showing neuronal/synaptic integrity [19, 20]. The
regional quantification is done by measurement of regional tracer concentration
normalized to body weight or surface as well as total injected dose, known as standardized
uptake value (SUV).
In patients with AD the temporoparietal, posterior cingulate and in advanced stages also
frontal cortex show hypometabolic changes reflecting neurodegenerative processes,
whereas other regions like primary motor and visual areas, cerebellum, thalamus and
basal ganglia nuclei are spared [21, 22]. Because of technical improvements and
consecutively higher spatial resolution of scans coupled with MRI co-registration,
abnormalities of hippocampal metabolism could be in addition better delineated [22-25].
These metabolic changes in 18F–FDG PET are characteristic providing the possibility to
identify AD with a sensitivity and specificity of 94% and 73%, respectively [21]. Thus, 18F–
FDG PET represents a valuable tool for differential diagnosis [26-30]. A high sensitivity of
18F-FDG PET for the diagnosis of dementia in very early stages such as in MCI has also
been demonstrated [31-33]. In addition, patients with MCI who show metabolic
abnormalities in specific cortical regions such as posterior cingulate cortex accompanied
by hypometabolism in parietotemporal cortex have a high risk for the development of AD
[34]. Finally, 18F–FDG PET may be used for objective follow-up of disease progression and
thus as a potential marker for evaluation of therapy [35, 36].
The results of several functional imaging studies using 18F–FDG PET in AD also fit very
well into the established map of hypometabolic abnormalities. For example, specific
correlations were seen between measures of episodic memory, verbal fluency and naming
and left hemispheric temporal and prefrontal metabolism [37, 38]. Recent results challenge
6the view that amnesia in early AD can be explained by the degree of mesial temporal lobe
damage alone while showing that semantic impairment can occur with damage restricted
to the rostral temporal lobes [39]. These papers show the ability of 18F-FDG PET in
establishing clinical settings.
However, it has to be taken into consideration that neurodegenerative processes in AD are
not evenly distributed in the brain of patients with AD. Even patients with clinically manifest
AD can show less affected cerebral regions and will maintain compensatory functions [40].
There is no linear relation between cognitive deficits and the changes of individual cerebral
activation, compensatory over-activation in some brain regions and breakdown of systems
in other regions may be present simultaneously during the course of ongoing
neurodegeneration. This would hamper the interpretation of 18F-FDG PET studies. In
addition, an age related decline of glucose metabolism [41] has to be taken into account
for correct interpretation of such metabolic studies.
Tracers on the trail of amyloid
Although investigations of PET on memory impairment have been mainly focused on 18F-
FDG, a variety of other tracers have been introduced in recent years. Of particular interest
is the development of tracers to label fibrillar Aß in vivo [42]. This development may be of
interest not only to support a clinical diagnosis of AD, but also to discriminate MCI
converters from non-converters to AD. Indeed, evidence of postmortem studies emphasize
that accumulation of amyloid plaques and NFTs occurs years before clinical manifestation
of AD [43]. Finally, such a technique may be of interest to monitor treatments for AD.
Several successful efforts have been done on imaging of amyloid plaques. More specific,
most studies in this field have been investigated with 11C-PIB (for “Pittsburg Compound-B”)
to visualize Aß plaques and 18F -FDDNP (Fluoroethylmethylamino-naphthylethylidene
malononitrile) which labels plaques and tangles [44-46].
([N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB,
Pittsburg Compound-B)
11C-PIB has been developed at the University of Pittsburgh. It is a derivate of thioflavin T
and shows high affinity for aggregated amyloid [47, 48]. In vivo 11C-PIB studies (Fig. 1)
demonstrate a nearly two-fold increase in tracer retention in AD patients compared to most
cognitively normal elderly subjects similar to the histopathologically known distribution of
AD-associated amyloid [45, 49]. These findings match studies of regional fibrillar plaque
distribution in autopsy [50-51]. The highest retention values were seen in prefrontal and
7lateral temporoparietal cortex, posterior cingulate/precuneus and striatum [52], whereas
occipital lobe and thalamus displayed lower uptake values. The lowest uptake values are
seen in the medial temporal lobe and primary visual and sensory motor cortical areas.
All clinically diagnosed AD patients showed PIB retention, while the majority of clinical
normal individuals did not. This is consistent with autopsy studies which find a pathological
diagnosis of AD in up to 30% of clinically asymptomatic subjects [52]. Interestingly, strong
spatial correlation exists between the topography of PIB deposition and default mode
functional MRI patterns [53].
PIB binding is absent in the majority of clinically diagnosed patients with frontotemporal
dementia and when present could represent either coexistent AD and frontal temporal lobe
dementia pathology or clinical misdiagnosis [54, 55]. Interestingly, the vast majority
(approximately 80%) of patients suffering from dementia with Lewy bodies (DLB) show
clearly increased PIB uptake in the brain.
High cortical uptake of 11C-PIB has been shown to be predictive of conversion of MCI to
AD thus having the potential for identification of the neuropathologic changes of AD in
clinically normal individuals, prior to the development of cognitive changes [56].
A recent ongoing project by the AD Neuroimaging Initiative (ADNI) will explore the
possibility of using PET and PIB as a tool for the development of neuroimaging and/or
biochemical markers that may serve as surrogate endpoints in MCI/AD clinical trials. The
project is part of a large public-private partnership on brain research and tracks normal,
mildly cognitively impaired, and AD brain changes to measure progression of the condition
[57].
11C-SB13 and 11C-BF-227
These tracers have been shown to have similar bindings in the brain compared to PIB
ligands [58]. Further studies are however needed to establish the clinical use or superiority
of these tracers compared to PIB.
However, the 20 minutes short half-life of 11C limits the use of 11C-PIB to centers with
cyclotron on-site. Recently a novel 18F labeled Aß tracer was introduced.
18F-FDDNP
18F-FDDNP [44] was one of the first PET-tracer in clinical trials in the field of amyloid
imaging. Retention of the compound was demonstrated in hippocampus, amygdala and
8enthorhinal cortex of AD patients compared to healthy controls. Significantly higher binding
in subjects with AD than those with MCI or control subjects and higher binding in MCI
patients than in control subjects have been reported. It has been shown that this tracer has
the potential to differentiate groups with MCI from those with AD and those with no
cognitive impairment [59]. The observed limitations are a low specific signal of only 0.3-
fold than that of the reference tissue in the regions of highest retention and also a high
non-specific binding in AD cases.
18F-BAY94-9172
In a recent study it was demonstrated that all AD patients had a widespread neocortical
binding of 18F-BAY94-9172, which was greater in the precuneus/posterior cingulate and
frontal cortex than in the lateral temporal and parietal cortex [60].
If one would like to use amyloid imaging as a biomarker either to monitor disease
progression or treatment effects, the outcome measure should correlate with
clinical/neuropsychological data. However, some 11C-PIB studies showed no significant
correlation with clinical data [45], while others did show such a correlation [61]. Moreover,
one study examined the feasibility to measure progression of PIB retention [62]. Engler
and co-workers [62] showed no significant difference in PIB retention between baseline
and follow-up while a significant decrease in regional cerebral metabolic rate for glucose
(rCMRGlc) was observed with 18F-FDG PET in cortical brain regions. In addition, a positive
correlation was observed in the parietal cortex between Rey Auditory Verbal Learning
(RAVL) test score and rCMRGlc at follow-up while a negative correlation (P = 0.018) was
observed between RAVL test and PIB retention in the parietal at follow-up.
Animal PET for Aß Imaging
In addition to human studies of Aß imaging, considerable research effort has been focused
on imaging Aß pathology in currently available animal models of AD with PET. This is
appealing as preclinical Aß imaging potentially allows for performing longitudinal studies in
order to asses the efficacy of new therapeutics directed against AD. Transgenic mouse
models like Tg2576 [63] and APP23 [64] became available in the mid-1990 and are
currently the most widely used animal model in AD-related research. First studies to
visualize the A load in the transgenic mouse brain with 11C-PIB or 18F-FDDNP were
unsuccessful. These findings were attributed to an about 1000-fold lower PIB binding site
density on A fibrils deposited in the transgenic mouse brain in comparison to human AD
brain [65-67]. However, in a recent study with 11C-PIB it has been shown that this limitation
9can be overcome by increasing the specific activity of the radiotracer to around 200
MBq/nmol, which led to an A -specific binding signal in the mouse brain that could be
quantified with small animal PET [46]. Interestingly, a triple-transgenic rat model of AD has
recently become available, which showed high hippocampal and cortical binding of 18F-
FDDNP. This could be displaced by the non-steroidal anti-inflammatory drug naproxen, a
competitive inhibitor of 18F-FDDNP binding, thereby suggesting specificity of 18F-FDDNP
binding in vivo. Rat models of AD are of considerable interest as the larger size of the rat
as compared to the mouse brain potentially helps to avoid imaging artifacts such as partial
volume or spill over effects, which can lead to difficulties in volume definition and
quantification of detailed brain regions. The potential of 18F-FDG to detect glucose
hypometabolism in regions of transgenic AD mice brain was shown by 14C-FDG ex-vivo
autoradiography [68, 69]. Significant reduction in 18F-FDG uptake was found in posterior
cingulated cortex of aged transgenic mice (PSAPP) compared to wild-type mice. However,
the limited spatial resolution of small animal PET scanners of around 1-2 mm appears to
preclude a successful translation of these findings to in vivo imaging with 18F-FDG [70].
Overall it appears that in preclinical PET imaging of AD the right animal model needs to be
carefully matched with the right radiotracer at the right specific activity [70].
MRI (Magnetic Resonance Imaging)
The role of MRI in the diagnosis of AD has been investigated in a number of papers.
Traditionally, MRI, or less preferable CT, is performed in patients with newly diagnosed
dementia in order to exclude other causes of dementia [71]. MRI, however, is also
increasingly used in the diagnosis of the AD [72]. The most prominent MRI finding in
patients with AD is a cortical atrophy which is frequently accentuated in the temporal lobe.
The most severely affected region is reported to be the subiculum of the parahippocampal
gyrus whose atrophy leads to an enlargement of the parahippocampal fissure [73]. The
enlargement of the parahippocampal fissure can be assessed by angeling the axial planes
parallel to the long axis of the hippocamus and the coronal planes perpendicular to it (Fig.
2). Also the measurement of other anatomical structures has been investigated in patients
with AD with variable success [72, 74]. Serial MRI studies allow to assess the atrophy rate
and have been used in a number of clinical trials as outcome measure [75].
Volumetric MRI evaluation of the hippocamus, the hippocamus and the amygdala may be
able to determine even subtle atrophy in elderly patients with MCI [76]. In a recent study it
was shown that medial and lateral temporal lobe atrophy as well as parietal cortex atrophy
on MR imaging characterized MCI converters to AD. Left temporal and left parietal cortex
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atrophy conveyed independent predictive value to delineate converters, a finding that is in
line with previous reports. This study was performed using Voxel-Based-Morphometry
(VBM) and SPM5 and Matlab 6.5. [77], methods which are in general not available in
routine hospitals.
Newer techniques such as microscopic application of magnetic resonance imaging have
shown promising results for visualization of senile plaques. Focused microscopic studies
were performed on parietal association cortex and it could be demonstrated that MR
microscopy is capable of directly visualizing cortical pathology in AD patients in vivo [78].
Another promising application of MRI in the evaluation of AD patients is MR spectroscopy
which allows to evaluate the metabolic changes associated with AD [79]. The neuronal
loss in AD is associated with a decrease of the neuronal marker N-acetylaspartate (NAA)
which can be measured by MR spectroscopy. The decrease of NAA is paralleled by an
increase of myo-inositol (MI), a metabolite of astrocytes surrounding the senile plaques
which can also be measured by MR spectroscopy. When using the MI/NAA quotient AD
can be distinguished from healthy subjects with a sensitivity of 83% and a specificity of
98% [80]. MR spectroscopy may also be helpful in the discrimination of early AD from
frontotemporal dementia [81].
The reduced cerebral blood flow in AD patients as seen on PET or SPECT can also be
visualized by dynamic susceptibility contrast enhanced MRI with a sensitivity of 90% [82].
Over the past years diffusion tensor imaging (DTI) has gained much attention in AD
research. DTI allows the visualization of fibre tracts arising from selected areas in the
brain. At this point it is not clear whether DTI is superior to conventional MRI in the
diagnosis of early AD or in discriminating AD from vascular dementia [83]. Early reports,
however, indicate that DTI may be a valuable tool in the diagnosis of early signs of MCI
[84].
Conclusion remarks
AD is a progressive neurodegenerative disease that affects the elderly population with a
prevalence of 10% in individuals older than 65 years but is higher than 40% in individuals
older than 85 years. With an increasing of the aging population in developed countries the
prevalence of dementia is rising, yielding to a major challenge for health institutions. As
mentioned earlier the annual conversion of patients with MCI to AD has been postulated to
be about 15 % per year. This stage of disease has been recognized as suitable for
possible therapeutic interventions.
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It is known that 18F-FDG PET has its limitations in diagnosis of very early preclinical
stages of AD and to overcome this combined assessment of medial temporal structures by
MRI have been proposed (33). More sophisticated diagnostic tracers are therefore
demanded to verify patients with MCI at risk to converse to AD which would have
implication for treatment strategies.
A number of tracers have been employed to study dementias and other neurodegenerative
diseases, using ligands to cholinergic receptors and cholinesterase enzymes, GABA-ergic,
dopaminergic transportes and serotonin receptors [86] which are not the scope of this
review and not discussed in detail. The role of these tracers for the routine clinical use
remains to be established by further ongoing studies.
The development of radioligands to image Aßmplaques and NFTs in vivo in the aging
human brain is an important and active area of research on AD. When used in
combination with PET or SPECT, amyloid-imaging tracers could facilitate diagnosis and
evaluation of the efficacy of anti-amyloid therapies currently under intense development.
Rather than the discussed Aß-tracers, lipophilic analogs of thioflavin S have been recently
synthesized and radiolabeled with positron or single photon emitting radionuclides for use
in PET and SPECT [87].
Because of the more widely spread of SPECT facilities, the development of
radiopharmaceuticals suitable for SPECT appear to be of interest.
However, PET has a better spatial resolution than SPECT, and quantitative measurements
are more sophisticated with PET than with SPECT.
Aß imaging with PET is a promising tool to study AD, since Aß deposits in the brain are
implicated in the pathogenesis of AD. In particular, Aß-42 has been suggested as the
primary cause of AD [88]. In vivo amyloid imaging targets the fibrillar form of Aß in amyloid
plaques. Several amyloid radiopharmaceuticals for PET have been investigated in the past
years such as the above mentioned 18F-FDDNP, 11C-BF-227, 11C-PIB and 18F-BAY94-
9172 [58]. According to recent studies, the cerebral binding of PIB seems to be a more
robust parameter for delineation of MCI converters to AD than other mentioned tracers.
Regarding the focus on anti-amyloid therapy, the amyloid imaging methods may enable to
delineate the patients at risk who could benefit from such treatment measures and also
may help to monitor the treatment response in patients with AD. However, on one hand,
the value of these methods in the differential diagnosis of AD still remains to be elucidated
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since PIB retention has been reported in LBD and also in a significant percentage of older
healthy subjects [51, 52]. On the other hand, at this stage of investigation, negative Aß-
imaging results may be helpful to exclude AD. This was shown in a study by Engler [55] for
differentiation of patients with frontal dementia from AD. In this study, it was found that
patients with frontal dementia had no evidence of cerebral amyloid deposition, a finding
which was confirmed by another recent study [54]. Phenserine, a cholinesteraseinhibitor
has been shown to decrease Aß in cell cultures [89]. The study group of Kadir et al.
showed that 11C-PIB PET had a reciprocal change between tracer retention in the brain
and Aß levels in CSF [90]. Improved cognitive function was correlated with reduced PIB
retention and CSF Aß levels. This is so far the first publication emphasizing the potential
role of amyloid imaging at least for assessment of new treatment strategies. Further
noninvasive longitudinal studies are necessary to better understand the role of amyloid
deposition in the course of neurodegeneration and to determine whether and at which
extent Aß deposition in non-demented subjects is a precursor to AD. Thus certain pattern
of amyloid deposition such as in the precuneus area can serve as a predictor of later onset
of AD.
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Fig. 1 (A,B):
11C-PIB PET images superimposed on individual MRI data. PET images in aged control
(A) and AD patient (B) were generated by averaging dynamic scan data from 30 to 90 min.
Signals were normalized by cerebellar values. (Images are friendly provided by: Huguchi
M. Molecular Neurobiology Section Molecular Imaging Center, National Institute of
Radiological Sciences, Chiba, Japan)
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Fig. 2 (A-D):
A) Parcoronal T1 weighted image from a 84 years old female patient with autopsy proven
Alzheimers’s disease showing significant hippocampal atrophy.
B-D)
Neuropathological hallmarks of Alzheimer´s disease include senile plaques which are
composed of extracellular fibrillar amyloid beta petides, mainly 1-40 and 1-42 (B), intra and
extracellular depositions of hyperphosphorylated microtubule associated protein tau (C;
i.e., neurofibrillary tangles, neuropil threads), and neuritic plaques which contain both
amyloid beta and hyperphosphorylated tau (D). B and D, modified Bielschowsky silver
stain; C, hyperphosphorylated tau antibody (clone AT8); original magnification x100 (B)
and x400 (C,D).
